FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase II drugs for Ewing Sarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the FPI-1434 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FPI-1434 overview
FP1-1434 is under development for the treatment of solid tumors, colorectal cancer, lung cancer, head and neck cancer squamous cell carcinoma, endometrial cancer, cervical cancer, ovarian cancer, triple-negative breast cancer, adrenocortical carcinoma (adrenal cortex cancer), uveal melanoma, human epidermal growth factor receptor 2 negative breast cancer, Ewing sarcoma and epidermoid carcinoma. The drug is a radionuclide drug conjugate (RDC) which contains monoclonal antibody conjugated to alpha particle-emitting cytotoxic isotope Actinium-225. It is administered through parenteral route. The therapeutic candidate acts by targeting cells expressing insulin-like growth factor-1 receptor (IGF-1R). It is developed based on Fusion’s fast-clear linker technology.
Fusion Pharmaceuticals overview
Fusion Pharmaceuticals, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company that develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059, FPI-2265 and FPI-1434. The company’s pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. It operates in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
For a complete picture of FPI-1434’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
